A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography

Biotechnology and Bioengineering

Volumn 90, Issue 4, 2005, Pages 391-404

  Segura, María De Las Mercedes ^a,b   Kamen, Amine ^b   Trudel, Pierre ^a,b   Garnier, Alain ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Gene therapy; Heparin affinity chromatography; Membrane filtration; Purification; Retrovirus; Stability

Indexed keywords

AFFINITY CHROMATOGRAPHY; BIOLOGICAL MEMBRANES; CENTRIFUGATION; GENES; GENETIC ENGINEERING; MICROFILTRATION; VIRUSES;

GENE THERAPY; HEPARIN AFFINITY CHROMATOGRAPHY; RETROVIRAL VECTORS; SIZE-EXCLUSION CHROMATOGRAPHY; ULTRACENTRIFUGATION;

PURIFICATION;

HEPARIN; RETROVIRUS VECTOR; SODIUM CHLORIDE; VIRUS DNA;

ADSORPTION; AFFINITY CHROMATOGRAPHY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA PURIFICATION; DOWNSTREAM PROCESSING; ELUTION; GEL PERMEATION CHROMATOGRAPHY; IMMOBILIZATION; IONIC STRENGTH; LIGAND BINDING; MEMBRANE BINDING; MEMBRANE DAMAGE; NONHUMAN; RETROVIRUS; SEPARATION TECHNIQUE; ULTRACENTRIFUGATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS TYPING;

CHROMATOGRAPHY, AFFINITY; GENE THERAPY; GENETIC VECTORS; HEPARIN; RETROVIRIDAE;

UNIDENTIFIED RETROVIRUS;

EID: 20344394438     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20301     Document Type: Article

References (45)

1. Aboud M, Wolfson M, Hassan Y, Huleihel M. 1982. Rapid purification of extracellular and intracellular Moloney murine leukemia virus. Arch Virol 71(3):185-195.
2. Alain R. 1997. Quantitation of virus particles by negative stain electron microscopy. Microsc Today 97:20.
3. Alain R, Nadon F, Seguin C, Payment P, Trudel M. 1987. Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids. J Virol Methods 16(3):209-216.
4. Andreadis ST, Roth CM, Le Doux JM, Morgan JR, Yarmush ML. 1999. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog 15(1):1-11.
5. Arai T, Matsumoto K, Saitoh K, Ui M, Ito T, Murakami M, Kanegae Y, Saito I, Cosset FL, Takeuchi Y, et al. 1998. A new system for stringent, high-liter vesicular stomatitis virus G protein-pseudotyped retrovirus vector induction by introduction of Cre recombinase into stable prepackaging cell lines. J Virol 72(2):1115-1121.
6. Beer C, Meyer A, Muller K, Wirth M. 2003. The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 308(1):137-146.
7. Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO. 1997. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 230(1):134-144.
8. Braas G, Searle PF, Slater NK, Lyddiatt A. 1996. Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 6(4):211-228.
9. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90(17): 8033-8037.
10. Cruz PE, Goncalves D, Almeida J, Moreira JL, Carrondo MJ. 2000. Modeling retrovirus production for gene therapy. 2. Integrated optimization of bioreaction and downstream processing. Biotechnol Prog 16(3):350-357.
11. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM. 2000. Virus attachment to host cells. In: Principles of virology: Molecular biology, pathogenesis and control. Washington: ASM Press, p 100-131.
12. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ. 1997. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology 230(1): 125-133.
13. Gomez-Navarro J, Curiel DT, Douglas JT. 1999. Gene therapy for cancer. Eur J Cancer 35(14):2039-2057.
14. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM. 1994. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6(4):335-341.
15. Guibinga GH, Miyanohara A, Esko JD, Friedmann T. 2002. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 5(5, Pt 1):538-546.
16. Hammarstedt M, Wallengren K, Pedersen KW, Roos N, Garoff H. 2000. Minimal exclusion of plasma membrane proteins during retroviral envelope formation. Proc Natl Acad Sci USA 97(13):7527-7532.
17. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346(16): 1185-1193.
18. Higashikawa F, Chang L. 2001. Kinetic analyses of stability of simple and complex retroviral vectors. Virol 280(1):124-131.
19. Jinno-Oue A, Oue M, Ruscetti SK. 2001. A unique heparin-binding domain in the envelope protein of the neuropathogenic PVC-211 murine leukemia virus may contribute to its brain capillary endothelial cell tropism. J Virol 75(24):12439-12445.
20. Kaufmann M. 1997. Unstable proteins: how to subject them to chromatographic separations for purification procedures. J Chromatogr B Biomed Sci Appl 699(1-2):347-369.
21. Kuiper M, Sanches RM, Walford JA, Slater NK. 2002. Purification of a functional gene therapy vector derived from Moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography. Biotechnol Bioeng 80(4):445-453.
22. Le Doux JM, Morgan JR, Snow RG, Yarmush ML. 1996. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 70(9):6468-6473.
23. Le Doux JM, Morgan JR, Yarmush ML. 1999. Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol Prog 15(3):397-406.
24. Lyddiatt A. 2002. Process chromatography: current constraints and future options for the adsorptive recovery of bioproducts. Curr Opin Biotechnol 13(2):95-103.
25. Lyddiatt A, O'Sullivan DA. 1998. Biochemical recovery and purification of gene therapy vectors. Curr Opin Biotechnol 9(2):177-185.
26. McGrath M, Witte O, Pincus T, Weissman IL. 1978. Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J Virol 25(3):923-927.
27. Navarro del Cañizo AA, Mazza M, Bellinzoni R, Cascone O. 1996. Foot and mouth disease virus concentration and purification by affinity chromatography. Appl Biochem Biotechnol 61(3):399-409.
28. Ory DS, Neugeboren BA, Mulligan RC. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93(21): 11400-11406.
29. O'Keeffe RS, Johnston MD, Slater NK. 1999. The affinity adsorptive recovery of an infectious herpes simplex virus vaccine. Biotechnol Bioeng 62(5):537-545.
30. Papadopulos-Eleopulos E, Turner VF, Papadimitriou JM. 1993. Is a positive western blot proof of HIV infection? Biotechnology (NY) 11(6):696-707.
31. Paquin A, Jaalouk DE, Galipeau J. 2001. Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum Gene Ther 12:13-23.
32. Parkman R, Weinberg K, Crooks G, Nolta J, Kapoor N, Kohn D. 2000. Gene therapy for adenosine deaminase deficiency. Annu Rev Med 51:33-47.
33. Pizzato M, Marlow SA, Blair ED, Takeuchi Y. 1999. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol 73(10):8599-8611.
34. Pizzato M, Merten OW, Blair ED, Takeuchi Y. 2001. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene Ther 8(10): 737-745.
35. Prior C, Bay P, Ebert B, Gore R, Holt J, Irish T, Jensen F, Leone C, Mitschelen J, Stiglitz M, Tarr C, Trauger RJ, Weber D, Hrinda M. 1995. Process development for the manufacture of inactivated HIV-1. BioPharmacology 8:25-35.
36. Richieri SP, Bartholomew R, Aloia RC, Savary J, Gore R, Holt J, Ferre F, Musil R, Tian HR, Trauger R and others. 1998. Characterization of highly purified, inactivated HIV-1 particles isolated by anion exchange chromatography. Vaccine 16(2-3):119-129.
37. Scherr M, Battmer K, Eder M, Schule S, Hohenberg H, Ganser A, Grez M, Blomer U. 2002. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther 9(24): 1708-1714.
38. Schidlovsky G. 1977. Structure of RNA Tumor Viruses. In: Gallo RC, editor. Recent advances in cancer research: Cell biology, molecular biology, and tumor virology. Vol I. Boca Raton, FL: CRC Press, p 189-245.
39. Smith RG, Lee SA. 1978. Large-scale isolation and partial purification of type C RNA viruses on hydroxyapatite. 1. Biochemical characterization. Anal Biochem 86(1):252-263.
40. Transfiguracion J, Jaalouk DE, Ghani K, Galipeau J, Kamen A. 2003. Size-exclusion chromatography purification of high-liter vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum Gene Ther 14(12):1139-1153.
41. Walker SJ, Pizzato M, Takeuchi Y, Devereux S. 2002. Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J Virol 76(14):6909-6918.
42. Weiss R. 1993. Cellular receptor and viral glycoproteins involved in retrovirus entry. In: Levy JA, editor. The retroviridae, Vol 2. New York: Plenum Press, p 1-108.
43. Williams DA, Baum C. 2003. Medicine. Gene therapy - New challenges ahead. Science 302(5644):400-401.
44. Yamada K, McCarty DM, Madden VJ, Walsh CE. 2003. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 34(5):1074-1078, 1080.
45. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6(6):973-985.